Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04768348
Other study ID # HMI-100-002
Secondary ID
Status Terminated
Phase
First received
Last updated
Start date April 20, 2021
Est. completion date August 1, 2023

Study information

Verified date August 2023
Source Homology Medicines, Inc
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The objective of this study is to characterize the natural history of phenylketonuria (PKU) due to phenylalanine hydroxylase (PAH) deficiency in adults through prospective collection of clinical, cognitive, and quality of life assessments.


Description:

Phenylalanine hydroxylase (PAH) deficiency is a rare disease caused by an inborn error of metabolism. If left untreated, PAH deficiency results in progressive, irreversible neurological impairment during infancy and early childhood. This study is designed to collect information about important PKU-related symptoms and tests to characterize the natural history of PKU due to PAH deficiency in a selected sample of adults. No new investigational treatment will be administered to participating patients.


Recruitment information / eligibility

Status Terminated
Enrollment 7
Est. completion date August 1, 2023
Est. primary completion date February 1, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 55 Years
Eligibility Key Inclusion Criteria: - Aged 18-55 years at the time of informed consent - Diagnosis of PKU due to PAH deficiency - One plasma Phe value with a concentration of = 600 µmol/L drawn at Screening and at least 1 historical Phe value = 600 µmol/L in the preceding 12 months Key Exclusion Criteria: - Subjects with PKU that is not due to PAH deficiency - Alanine aminotransferase (ALT) > 1.5x upper limit of normal (ULN) and aspartate aminotransferase (AST) >1.5x ULN - Alkaline phosphatase > 1.5x ULN - Total bilirubin > 1.5x ULN, direct bilirubin = 1.5x ULN, unless associated with Gilbert's syndrome. - Serum creatinine > 1.5x ULN - Hematology values outside of the normal range (hemoglobin < 11.0 g/dL for males or < 10.0 g/dL for females; white blood cells (WBC) < 3,000/µL; absolute neutrophils < 1,500/µL; platelets < 100,000/µL) - Hemoglobin A1c > 6.5% or fasting glucose > 126 mg/dL - Any clinically significant abnormal laboratory result at Screening, as determined by the Investigator

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States Emory University Hospital Atlanta Georgia
United States UT Southwestern Medical Center Dallas Texas
United States Kaiser Permanente Los Angeles Medical Center Los Angeles California
United States Children's Hospital of Orange County Orange California
United States University of Pittsburgh Medical Center- CHOP Pittsburgh Pennsylvania
United States University of Utah Health Salt Lake City Utah
United States University of South Florida Tampa Florida
United States Community Health Clinic Topeka Indiana

Sponsors (1)

Lead Sponsor Collaborator
Homology Medicines, Inc

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Plasma phenylalanine (Phe) concentrations Change in plasma Phe concentrations throughout study duration Baseline to Week 52
Primary Plasma tyrosine (Tyr) concentrations Change in plasma Tyr concentrations throughout study duration Baseline to Week 52
Primary Quality of life (QOL), as assessed using the PKU-QOL questionnaire measures Changes in PKU-QOL Baseline to Week 52
See also
  Status Clinical Trial Phase
Recruiting NCT05998109 - PheCheck Feasibility Study
Not yet recruiting NCT04433728 - Life With Phenylketonuria. Adult Neurological Outcome of PCU Screened Patients From 1971 to 2002.
Completed NCT01209819 - Bone Mineral Density in Adults With Hyperphenylalaninemia N/A
Active, not recruiting NCT05174559 - Additional Dietary Large Neutral Amino Acids (LNAA) for Improved Symptoms in Adult Classical Phenylktonuria (PKU) N/A
Not yet recruiting NCT04969809 - Comparison of Atherogenic Risk Factors and Efficacy of Nutritional Treatment Among Adult Phenylketonuria Patients N/A
Recruiting NCT04404530 - Nutritional Impacts of Palynziq on Patients With Phenylketonuria (PKU)
Recruiting NCT05827536 - Open-label, Randomized, 2-way Crossover, Monocentric, Controlled Study to Evaluate the Effect on Daily PHE Fluctuation of PKU GOLIKE Versus SoC in Patients With PKU. N/A
Active, not recruiting NCT05971563 - Amino Acid Kinetics of GMP-AA in Healthy Human Volunteers N/A
Enrolling by invitation NCT03655223 - Early Check: Expanded Screening in Newborns
Completed NCT04368624 - PKU Skin Stripping
Completed NCT04452513 - A Prospective Clinical Study of Phenylketonuria (PKU)
Completed NCT05497050 - The Effect of Nursing Empowerment Program N/A
Completed NCT04943393 - Remote Neurocognitive and Psychological Assessment in PKU
Completed NCT05096988 - Evaluation of PKU Sphere Liquid N/A
Not yet recruiting NCT06332807 - AAV Gene Therapy Clinical Study in Adult Classic PKU Phase 1/Phase 2
Completed NCT00225615 - A Phase 3, Multicenter, Open-Label Extension Study of Phenoptin in Subjects With PKU Who Have Elevated Phenylalanine Levels Phase 3
Recruiting NCT05128149 - Metabolic Control and Patient Well-being in Phenylketonuria: do Guidelines Make a Difference?
Terminated NCT05229549 - Study to Evaluate the Effect on Nitrogen Retention of Two Different Posology Schemes of PKU GOLIKE PLUS 3-16 and Free AAs in Patients With Phenylketonuria N/A
Enrolling by invitation NCT05356377 - Preliminary Study of Brain Effects of Palynziq-Related Changes in Phenylalanine in Individuals With PKU
Not yet recruiting NCT06337864 - Evaluating the Efficacy and Safety of Large Neutral Amino Acids in the Treatment of Classical Phenylketonuria N/A